Early-stage cell therapy startup March Biosciences has partnered with CTMC. Photo via march.bio

When it came time to name their cell therapy startup, Houston life science innovators simply had to look to their calendar.

“I would argue that March is the best month in Houston,” Sarah Hein tells InnovationMap. “We started talking about putting this company together during COVID, so we were outside a lot. And we actually got together in March.”

That’s why the CEO and her co-founders Max Mamonkin and Malcolm Brenner decided to name their company March Biosciences.

It's a fresh, unstuffy name for a startup that has an innovative take on cancer immunotherapy. Their lead asset is an advanced cellular therapy known as MB-105, an autologous CD5 CAR T cell therapy. For patients with T-cell lymphoma and leukemia who have failed all currently available lines of therapy, the prognosis is understandably extremely poor. But in a phase one study, MB-105 has been proven to safely treat those patients. The phase two study is expected to begin in the first half of 2024.

Hein met Mamonkin at the TMC Accelerator for Cancer Therapeutics (ACT), at which the alumna of Resonant Therapeutics and Courier Therapeutics was an entrepreneur in residence.

“It's a perfect example of the opportunities here in Houston where you can go from bench to bedside, essentially, in the same institution. And Baylor has been particularly good at that because of the Center for Cell and Gene Therapy,” says Hein.

The serial entrepreneur first came to Houston as a PhD student in molecular and cellular biology at Baylor College of Medicine, but during her studies she became excited by the startup ecosystem in her new hometown. After earning her degree, she became a venture fellow at the Mercury Fund. Her experience in both science and business made her an ideal candidate to take March Biosciences to the next level.

In September, the company announced that it formed a strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience.

“Our unique risk-sharing model allows us to collaborate with organizations like March Biosciences to accelerate the development and manufacture of innovative cell therapies, like MB-105, and bring them into the clinic with a consistent and scalable manufacturing process,” said CTMC’s CEO, Jason Bock in a press release.

The partnership “has allowed us to move really quickly,” Hein says.

That’s because what CTMC does uniquely well is take early stage companies like March Biosciences and advance them to a state that’s ready for manufacturing in a short time, around 18 months, says Hein.

According to Hein, March Biosciences’ success is a testament to Houston and its world-class medical center.

“It’s a great example of the opportunities you see here in Houston, where we have a technology that was developed by brilliant scientists here in Houston and we can pull together the resources that we need to take it to the next level,” Hein says. "Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

This week's roundup of Houston innovators includes Jason Bock of CTMC, Barbara Burger, and Mario Amaro of Ease. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from cell therapy to energy transition — recently making headlines in Houston innovation.

Jason Bock, founder and CEO of CTMC

Jason Bock, founder and CEO of the Cell Therapy Manufacturing Center, joins the Houston Innovators Podcast to explain the complicated — yet necessary — process of scaling cell therapies. Photo courtesy

Last year, a project out of MD Anderson spun out to create a new joint venture, CTMC — Cell Therapy Manufacturing Center, with National Resilience, a company that was founded to help advance life-saving therapeutics. The JV is based in the Texas Medical Center and led by CEO Jason Bock, who says the entity's location is critical.

"Houston has a chance to play a role in all aspects of cell therapy," he says, from discovery to the clinical side. "Some really interesting cell therapies that are in development were discovered here in Houston."

Bock shares more on how the impact CTMC is making on cell therapy advancement on the podcast. Read more.

Barbara J. Burger, startup adviser and mentor 

Energy innovation expert, Barbara Burger, shares how she sees the future of energy playing out as a dance between mice — the startups — and elephants — the incumbent corporations. Photo courtesy

The way Barbara Burger sees it, the energy transition depends on a dance between startups, or the mice, and corporates, aka the elephants. In a guest column for InnovationMap, she explains what questions each side needs to address.

"There are lots of questions here and the why is often an iterative journey for both sides," she explains. "It is as much mindset, influence, strategy, champions, and risk tolerance at individual levels as it about technology and economics." Read more.

Mario Amaro, CEO and founder of Ease

Mario Amaro, founder of Ease, was selected for one of Amazon's accelerator programs. Photo courtesy of Amazon

Amazon's AWS Impact Accelerator Latino Founders Cohort named the 20 startups joining its accelerator that will connect Latinx founders to its network of mentors, provide programming, and even dole out funding.

Houston-based Ease, founded by Mario Amaro in 2018, the health care fintech platform allows for medical professionals to start, grow, and manage their private practices with bookkeeping tools and other software infrastructure. So far, the company has worked with more than 300 practices. Read more.

Jason Bock, founder and CEO of the Cell Therapy Manufacturing Center, joins the Houston Innovators Podcast to explain the complicated — yet necessary — process of scaling cell therapies. Photo courtesy

Houston innovator aims to scale cancer-curing cell therapies

HOUSTON INNOVATORS PODCAST EPISODE 185

It's almost unreal what can be done with therapeutics today, especially in the specialty of cell therapy.

"It feels like science fiction," says Jason Bock, founder and CEO of the Cell Therapy Manufacturing Center, or CTMC, a joint venture between National Resilience and MD Anderson Cancer Center.

Cell therapy is essentially personalized medicine, he explains. The process includes taking out a patient’s own immune cells, identifying specifically the T-cells, and engineer them to have them target cancer before expanding them and reintroducing them to the patient.

“The supply chain begins with the patient,” Bock explains on the Houston Innovators Podcast. “If the patient is going to be an integral part of the supply chain, one way to simplify your supply chain is to locate your manufacturing very close to where your patients are.”

That's where CTMC, located in the heart of the Texas Medical Center, comes in. Bock moved to Houston from the East Coast four years to stand up the program at MD Anderson. The founding thesis was to work with faculty members who have interesting ideas for biologics or cell therapies, help them industrialize them, and then bring them into the MD Anderson clinic to evaluate in patients.

Last year, the entity spun out into a joint venture structure with National Resilience, a company that was founded amid the pandemic to build resilience in the nation for complex biologics manufacturing — like vaccines, for instance — in order to expedite the process of getting these treatments to patients.

With access to patients established, how do you address scalability of this treatment in a field that's so customized?

While it might sound like a challenge to scale personalized medicine — it's a worthwhile challenge. Bock says that even though cell therapy is in its early stages still — the first treatment was approved by the FDA just five years ago — early studies have shown patients, who essentially have no other treatment options, can see life-saving results in as little as one treatment.

"We see in a large group of patients — 30 to 50 percent of patients — are cured with one dose," he says on the show.

CTMC has a 60,000-square-foot space two blocks away from MD Anderson. This critical lab space with 14 clean rooms was made available after its previous biotech tenant moved out. The setup can support up to 140 people, and the organization has grown to 80 people over the past few years.

Bock says CTMC is an engine for cell therapy research — one that can take a therapeutic from research to the clinic in about one to two years. Every year, he says CTMC can roll three to five therapeutics into the clinic phase.

And, Houston's an ideal place to do that.

"Houston has a chance to play a role in all aspects of cell therapy," he says, from discovery to the clinical side. "Some really interesting cell therapies that are in development were discovered here in Houston."

Bock shares more on how the impact CTMC is making on cell therapy advancement on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7 can't miss Houston business and innovation events for July

where to be

Editor's note: While many Houstonians are flocking to vacation destinations, there are still plenty of opportunities to network and learn at tech and business events for those sticking close to home this month. From an inaugural biotech summit to the 12th edition of a local pitch showcase, here are the Houston business and innovation events you can't miss in July and how to register. Please note: this article might be updated to add more events.

July 10 - Out in Tech Mixer 

Out in Tech Houston provides an inclusive networking space for LGBTQ+ people and allies working in tech. Check out this relaxed, social-mixer event, hosted on the second Thursday of every month.

This event is Thursday, July 10, from 7 to 8:30 p.m. at Second Draught. Register here.

July 14 – Latinas in Tech Coworking Day 

Connect with fellow Latinas in the industry at Sesh Coworking. Network or work alongside peers, board members and community leaders in a shared office environment.

This event is Monday, July 14, from 9-11:30 a.m. at Sesh Coworking. Find more information here.

July 17 – UTMB Innovation VentureX Summit

Attend the inaugural UTMB Innovation VentureX Summit, where innovators, entrepreneurs, researchers and investors will dive into the future of biotech. Expect panel discussions, fireside chats, a technology showcase and networking opportunities.

This event is Thursday, July 17, from 7:30 a.m.-4 p.m. at The University of Texas Medical Branch at Galveston. Find more information here.

July 17 – Open Project Night 

Collaborate on solutions for some of Houston’s most pressing issues at this month’s Open Project Night at Impact Hub Houston. Hear from guest speakers and listen to open mic pitches. July’s theme is Decent Work & Economic Growth.

This event is Thursday, July 17, from 5:30-7:30 p.m at Impact Hub Houston. Register here.

July 24 – NASA Tech Talks

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, July 24, from 6-7 p.m. at the Ion. Register here.

July 30 – Ion Bike Club

Join Bike Houston at the Ion for a 45-minute guided cruise through the Ion District and Midtown. Afterward, enjoy a complimentary beer and network with like-minded riders at Second Draught.

This event is Wednesday, July 30, from 5:30-7:30 p.m. at the Ion. Register here.

July 31 – Bayou Startup Showcase

Hear pitches from startups and small businesses from Rice University’s OwlSpark and the University of Houston’s RED Labs accelerators at the 12th annual Bayou Startup Showcase. Read more about this year’s teams here.

This event is Thursday, July 31, from 3:30-7 p.m. at the Ion. Register here.

Houston researchers: Here's what it takes to spot a great new idea

houston voices

Having a “promotion focus” really does create a mental lens through which new ideas are more visible.

Key findings:

  • New ideas can be crucially important to businesses, driving innovation and preventing stagnation.
  • Recognizing those ideas, though, isn’t always easy.
  • Nurturing what is known as “promotion focus” can help managers spot fresh ideas.

Whenever the late surgeon Michael DeBakey opened a human chest, he drew on a lifetime of resources: the conviction that heart surgery could and should be vastly improved, the skill to venture beyond medicine’s known horizons and the vision to recognize new ideas in everyone around him, no matter how little formal training they had.

Appreciating new ideas is the heartbeat of business as well as medicine. But innovation is surprisingly hard to recognize. In a pioneering 2017 article, Rice Business Professor Jing Zhou and her colleagues published their findings on the first-ever study of the traits and environments that allow leaders to recognize new ideas.

Recent decades have produced a surge of research looking at how and when employees generate fresh ideas. But almost nothing has been written on another crucial part of workplace creativity: a leader’s ability to appreciate new thinking when she sees it.

Novelty, after all, is what drives company differentiation and competitiveness. Work that springs from new concepts sparks more investigation than work based on worn, already established thought. Companies invest millions to recruit and pay star creatives.

Yet not every leader can spot a fresh idea, and not every workplace brings out that kind of discernment. In four separate studies, Zhou and her coauthors examined exactly what it takes to see a glittering new idea wherever it appears. Their work sets the stage for an entirely new field of future research.

First, though, the team had to define their key terms. “Novelty recognition” is the ability to spot a new idea when someone else presents it. “Promotion focus,” previous research has shown, is a comfort level with new experiences that evokes feelings of adventure and excitement. “Prevention focus” is the opposite trait: the tendency to associate new ideas with danger, and respond to them with caution.

But does having “promotion focus” as opposed to “prevention focus” color the ability to see novelty? To find out, Zhou’s team came up with an ingenious test, artificially inducing these two perspectives through a series of exercises. First, they told 92 undergraduate participants that they would be asked to perform a set of unrelated tasks. Then the subjects guided a fictional mouse through two pencil and paper maze exercises.

While one exercise showed a piece of cheese awaiting the mouse at the end of the maze (the promise of a reward), the other maze depicted a menacing owl nearby (motivation to flee).

Once the participants had traced their way through the mazes with pencils, they were asked to rate the novelty of 33 pictures — nine drawings of space aliens and 24 unrelated images. The students who were prepped to feel an adventurous promotion focus by seeking a reward were much better at spotting the new or different details among these images than the students who’d been cued to have a prevention focus by fleeing a threat.

The conclusion: a promotion focus really does create a mental lens through which new ideas are more visible.

Zhou’s team followed this study with three additional studies, including one that surveyed 44 human resource managers from a variety of companies. For this study, independent coders rated the mission statements of each firm, assessing their cultures as “innovative” or “not innovative.” The HR managers then evaluated a set of written practices — three that had been in use for years, and three new ones that relied on recent technology. The managers from the innovative companies were much better at rating the new HR practices for novelty and creativity. To recognize novelty, in other words, both interior and external environments make a difference.

The implications of the research are groundbreaking. The first ever done on this subject, it opens up a completely new research field with profound questions. Can promotion focus be created? How much of this trait is genetic, and how much based on natural temperament, culture, environment and life experience? Should promotion focus be cultivated in education? If so, what would be the impact? After all, there are important uses for prevention focus, such as corporate security and compliance. Meanwhile, how can workplaces be organized to bring out the best in both kinds of focus?

Leaders eager to put Zhou’s findings to use right away, meanwhile, might look to the real-world model of Michael DeBakey. Practice viewing new ideas as adventures, seek workplaces that actively push innovation and, above all, cultivate the view that every coworker, high or low, is a potential source of glittering new ideas.

---

This article originally appeared on Rice Business Wisdom.

Jing Zhou is the Mary Gibbs Jones Professor of Management and Psychology in Organizational Behavior at the Jones Graduate School of Business of Rice University. Zhou, J., Wang, X., Song, J., & Wu, J. (2017). "Is it new? Personal and contextual influences on perceptions of novelty and creativity." Journal of Applied Psychology, 102(2): 180-202.